Bladder cancer: Meta-analysis of BCG versus mitomycin C-a deeper insight?

Nature Reviews Urology

Volumn 7, Issue 1, 2010, Pages 8-10

  Böhle, Andreas ^a  

^a HELIOS AGNES KARLL HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; MITOMYCIN;

BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RISK; COMPARATIVE STUDY; DRUG EFFICACY; EUROPE; HIGH RISK PATIENT; HUMAN; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; SHORT SURVEY; UNITED STATES;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; HUMANS; META-ANALYSIS AS TOPIC; MITOMYCIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 75949106780     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.253     Document Type: Short Survey

References (8)

1. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303-314 (2008).
2. Persad, R. A. et al. Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur. Urol. 7 (suppl.), 637-650 (2008).
3. Huncharek, M., McGarry, R. & Kupelnick, B. impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 21, 765-770 (2001).
4. sylvester, R. J. Bacillus Calmette-Guerin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues. Eur. Urol. 56, 266-268 (2009).
5. Dalbagni, G. is intravesical Bacillus Calmette-Guerin better than mitomycin for intermediate-risk bladder cancer? Eur. Urol. 56, 257-258 (2009).
6. Jarvinen, R., Kaasinen, E., sankila, A. & Rintala, e. Long-term efficacy of maintenance Bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder i study with a 20-year follow-up. Eur. Urol. 56, 260-265 (2009). 7. Malmström, P. U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur. Urol. 56, 247-256 (2009).
7. Böhle, A., Jocham, D. & Bock, P. R. intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 169, 90-95 (2003).
8. Böhle, A. & Bock, P. R. intravesical Bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63, 682-686 (2004). 10. sylvester, R. J., van der Meijden, A. P. M. & Lamm, D. L. Intravesical Bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964-1970 (2002).